NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM TrialPRNewsWire • 02/21/24
NeuroSense's (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024Accesswire • 01/30/24
NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 CatalystsPRNewsWire • 01/09/24
NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity RequirementPRNewsWire • 12/27/23
“Exceptional Result”: NeuroSense Therapeutics Reports New Positive Data from ALS TrialMCAP MediaWire • 12/15/23
NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS TrialPRNewsWire • 12/14/23
NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy EndpointsPRNewsWire • 12/05/23
NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023PRNewsWire • 12/04/23
NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business UpdatePRNewsWire • 11/28/23
NeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial ReadinessPRNewsWire • 11/13/23
NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS ConferencesPRNewsWire • 11/09/23
NeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023PRNewsWire • 11/06/23
Renowned ALS Researcher Confirms The Efficacy Of NeuroSense Therapeutics' Lead Drug Candidate, PrimeCAccesswire • 10/19/23
NeuroSense's PrimeC Demonstrates Outstanding Effect on ALS Survival in Innovative iPSC ModelPRNewsWire • 10/04/23
NeuroSense to Participate in Upcoming ALS Conferences: PACTALS in Malaysia and NEALS in the U.S.PRNewsWire • 09/14/23
NeuroSense Announces Second Quarter 2023 Financial Results and Provides Business UpdatePRNewsWire • 08/16/23
NeuroSense to Participate in Upcoming ALS Conferences: European Network to Cure ALS & EverythingALS Digital Biomarkers SummitPRNewsWire • 07/11/23